Perseus Holdings

Perseus Holdings is a clinical-stage immuno-oncology company based in Austin, Texas, focused on the development of personalized therapeutic cancer vaccines. Operating primarily through its wholly owned subsidiary, Elios Therapeutics, the company is advancing its lead candidate, the TLPLDC (tumor lysate, particle-loaded, dendritic cell) vaccine, which is currently in Phase 3 clinical trials for the treatment of high-risk melanoma. The TLPLDC platform utilizes a proprietary delivery system involving yeast cell wall particles to present a patient's unique tumor antigens to their immune system, aiming to trigger a robust T-cell response. In addition to melanoma, the company has explored applications for its technology in other solid tumors, including ovarian cancer.